STOCK TITAN

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Black Diamond Therapeutics, Inc. (BDTX) will be presenting at various investor conferences to discuss their MasterKey therapies targeting oncogenic mutations in cancer patients. The presentations will be held in April 2024, featuring President and CEO, Mark Velleca, M.D., Ph.D.
Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass. and NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D., are as follows:

  • 23rd Annual Needham Virtual Healthcare Conference presentation at 8:00am ET on Wednesday, April 10, 2024
  • Stifel Virtual Targeted Oncology Forum fireside chat at 10:00am ET on Tuesday, April 16, 2024
  • Piper Sandler Spring Biopharma Symposium on Wednesday, April 17, 2024, in Boston, Mass.

Webcasts will be available at the start of the presentations on the investor relations section of the Company’s website, www.blackdiamondtherapeutics.com. Replays of the presentations will also be available and archived on the site for 90 days.

About Black Diamond Therapeutics

Black Diamond Therapeutics is a clinical-stage oncology company focused on the development of MasterKey therapies that address families of oncogenic mutations in clinically validated targets. The Company’s MasterKey therapies are designed to address broad genetically defined patient populations, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat CNS disease. The Company is advancing two clinical-stage programs: BDTX-1535, a brain-penetrant fourth-generation EGFR MasterKey inhibitor targeting EGFR mutant NSCLC and GBM, and BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors. For more information, please visit www.blackdiamondtherapeutics.com

Contacts

For Investors:
Mario Corso, Head of Investor Relations, Black Diamond Therapeutics
mcorso@bdtx.com

For Media:
media@bdtx.com


FAQ

When is Black Diamond Therapeutics, Inc. (BDTX) participating in the 23rd Annual Needham Virtual Healthcare Conference?

Black Diamond Therapeutics, Inc. (BDTX) is presenting at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024, at 8:00am ET.

Who will be the speaker at the Stifel Virtual Targeted Oncology Forum fireside chat for Black Diamond Therapeutics, Inc. (BDTX)?

The speaker at the Stifel Virtual Targeted Oncology Forum fireside chat for Black Diamond Therapeutics, Inc. (BDTX) will be President and CEO, Mark Velleca, M.D., Ph.D.

Where will the Piper Sandler Spring Biopharma Symposium take place for Black Diamond Therapeutics, Inc. (BDTX)?

The Piper Sandler Spring Biopharma Symposium for Black Diamond Therapeutics, Inc. (BDTX) will be held in Boston, Mass., on Wednesday, April 17, 2024.

How long will the replays of Black Diamond Therapeutics, Inc. (BDTX) presentations be available on their website?

The replays of Black Diamond Therapeutics, Inc. (BDTX) presentations will be available and archived on their website for 90 days.

Black Diamond Therapeutics, Inc.

NASDAQ:BDTX

BDTX Rankings

BDTX Latest News

BDTX Stock Data

312.03M
35.92M
2.61%
93.57%
3.95%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
CAMBRIDGE

About BDTX

black diamond therapeutics, inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. its lead product candidate is bdtx-189, an inhibitor of non-canonical and oncogenic mutations of erbb kinases epidermal growth factor receptor (egfr) and tyrosine-protein kinase. the company is also developing allosteric-egfr mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. the company was formerly known as aset therapeutics, inc. and changed its name to black diamond therapeutics, inc. in january 2018. black diamond therapeutics, inc. was founded in 2014 and is headquartered in cambridge, massachusetts.